WO2010119257A3 - Internal ribosome entry site from marek' s disease virus - Google Patents

Internal ribosome entry site from marek' s disease virus Download PDF

Info

Publication number
WO2010119257A3
WO2010119257A3 PCT/GB2010/000763 GB2010000763W WO2010119257A3 WO 2010119257 A3 WO2010119257 A3 WO 2010119257A3 GB 2010000763 W GB2010000763 W GB 2010000763W WO 2010119257 A3 WO2010119257 A3 WO 2010119257A3
Authority
WO
WIPO (PCT)
Prior art keywords
ires
marek
disease virus
entry site
internal ribosome
Prior art date
Application number
PCT/GB2010/000763
Other languages
French (fr)
Other versions
WO2010119257A2 (en
Inventor
Abdou Tahiri-Alaoui
Vincent Mauro
Venugopal Nair
Original Assignee
Institute For Animal Health
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute For Animal Health, The Scripps Research Institute filed Critical Institute For Animal Health
Publication of WO2010119257A2 publication Critical patent/WO2010119257A2/en
Publication of WO2010119257A3 publication Critical patent/WO2010119257A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/60—Vectors comprising a special translation-regulating system from viruses

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides an internal ribosome entry site (IRES) sequence derivable from the IRES located in the 5' untranslated region (UTR) of the pl4 lytic protein from Marek's disease virus (MDV-I). The IRES may comprise the sequence shown in figure 1 or a part or variant thereof. The present invention also provides a construct comprising such an IRES and a cistron; a nucleotide sequence comprising or capable of encoding such an IRES or construct and a vector comprising such a nucleotide sequence. The vector may be used as a pharmaceutical composition.
PCT/GB2010/000763 2009-04-16 2010-04-15 Internal ribosome entry site WO2010119257A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0906576.4 2009-04-16
GB0906576A GB0906576D0 (en) 2009-04-16 2009-04-16 Internal ribosome entry site

Publications (2)

Publication Number Publication Date
WO2010119257A2 WO2010119257A2 (en) 2010-10-21
WO2010119257A3 true WO2010119257A3 (en) 2010-12-09

Family

ID=40750724

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2010/000763 WO2010119257A2 (en) 2009-04-16 2010-04-15 Internal ribosome entry site

Country Status (2)

Country Link
GB (1) GB0906576D0 (en)
WO (1) WO2010119257A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
US11365391B2 (en) 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
CN113699154B (en) * 2021-10-27 2022-02-11 和元生物技术（上海）股份有限公司 IRES mutant and application thereof
EP4253418A1 (en) 2022-03-29 2023-10-04 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FILBIN MEGAN E ET AL: "Toward a structural understanding of IRES RNA function.", CURRENT OPINION IN STRUCTURAL BIOLOGY JUN 2009 LNKD- PUBMED:19362464, vol. 19, no. 3, 9 April 2009 (2009-04-09), pages 267 - 276, XP002593681, ISSN: 1879-033X *
HONG Y ET AL: "A 14-kDa immediate-early phosphoprotein is specifically expressed in cells infected with oncogenic Marek's disease virus strains and their attenuated derivatives", VIROLOGY, ACADEMIC PRESS,ORLANDO, US LNKD- DOI:10.1016/S0042-6822(95)80091-3, vol. 206, no. 1, 10 January 1995 (1995-01-10), pages 695 - 700, XP004786698, ISSN: 0042-6822 *
HONG Y ET AL: "Identification of an immediate-early gene in the Marek's disease virus long internal repeat region which encodes a unique 14-kilodalton polypeptide.", JOURNAL OF VIROLOGY JUN 1994 LNKD- PUBMED:8189498, vol. 68, no. 6, June 1994 (1994-06-01), pages 3593 - 3603, XP002593683, ISSN: 0022-538X *
PENG F ET AL: "Isolation and characterization of cDNAs from BamHI-H gene family RNAs associated with the tumorigenicity of Marek's disease virus.", JOURNAL OF VIROLOGY DEC 1992 LNKD- PUBMED:1279201, vol. 66, no. 12, December 1992 (1992-12-01), pages 7389 - 7396, XP002593680, ISSN: 0022-538X *
TAHIRI-ALAOUI A ET AL: "Identification of an intercistronic internal ribosome entry site in a Marek's disease virus immediate-early gene", JOURNAL OF VIROLOGY 2009 AMERICAN SOCIETY FOR MICROBIOLOGY USA LNKD- DOI:10.1128/JVI.02602-08, vol. 83, no. 11, 18 March 2009 (2009-03-18), pages 5846 - 5853, XP002593682, ISSN: 0022-538X *
TAHIRI-ALAOUI ABDESSAMAD ET AL: "The 5 ' Leader of the mRNA Encoding the Marek's Disease Virus Serotype 1 pp14 Protein Contains an Intronic Internal Ribosome Entry Site with Allosteric Properties", JOURNAL OF VIROLOGY, vol. 83, no. 24, December 2009 (2009-12-01), pages 12769 - 12778, XP002593684 *

Also Published As

Publication number Publication date
WO2010119257A2 (en) 2010-10-21
GB0906576D0 (en) 2009-05-20

Similar Documents

Publication Publication Date Title
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
WO2008036146A3 (en) Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
WO2010057203A3 (en) Hdl particles for delivery of nucleic acids
MX2019002345A (en) Artificial nucleic acid molecules for improved protein or peptide expression.
WO2008121324A3 (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
MX2011008094A (en) Extended recombinant polypeptides and compositions comprising same.
NZ609903A (en) Expression vector for high level expression of recombinant proteins
WO2008153745A3 (en) Compositions and methods for producing bioactive fusion proteins
IL215451A (en) Antigenic constructs comprising an antigenic peptide of the tau protein and pharmaceutical compositions comprising same
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
WO2010150233A3 (en) Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
WO2012083078A3 (en) Croos-linked peptides and proteins, methods of making same, and uses thereof
SG195194A1 (en) Nanogels
EP1989316A4 (en) Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions
WO2004081028A3 (en) Allergen peptide fragments and use thereof
WO2007119011A3 (en) N protein fusion proteins of a virus in the paramyxoviridae-protein of interest family
EP2234636A4 (en) Stabilized formulations of peptides and proteins
WO2010119257A3 (en) Internal ribosome entry site from marek' s disease virus
WO2013060819A3 (en) Transient expression vectors, preparation and uses thereof
WO2009120380A3 (en) Recombinant rhinovirus vectors
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
WO2009064366A3 (en) Methods and compositions for protein labeling using lipoic acid ligases
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2013040478A3 (en) Hyr1-derived compositions and methods of treatment using same
WO2013036622A3 (en) Antiviral peptides effective against hepatitis c virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10714353

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10714353

Country of ref document: EP

Kind code of ref document: A2